Skip to main content
Premium Trial:

Request an Annual Quote

Neuromuscular Consortium to Use Roche NimbleGen Arrays

NEW YORK (GenomeWeb News) – Roche announced today that the Neuromuscular Disorder-Chip Consortium has selected Roche NimbleGen microarrays for its genetic research on neuromuscular disorders (NMDs).

The researchers will use custom-designed NimbleGen Human CGH 12x135K microarrays to look for NMD-related gene and exon level rearrangements, deletions, or insertions — particularly for NMDs such as Duchenne/Becker muscular dystrophies, limb girdle muscular dystrophies, congenital muscular dystrophies, hereditary motor-sensory neuropathies, and Charcot-Marie-Tooth neuropathies.

The consortium also plans to use customized NimbleGen Human Sequence Capture 385K arrays for capturing DNA fragments representing all known genes in groups of NMDs. These fragments can then be coupled with high-throughput sequencing to assess genetic variation in NMDs.

The NMD-Chip Consortium, a European Union Seventh Framework Programme for Research and Technical Development, includes researchers from 13 European institutions in eight countries. The consortium's goals are to not only learn more about the genetics underpinning NMDs, but also to try to find faster and more cost-effective ways to study and diagnose the conditions. Inherited NMDs affect roughly one in 1,000 people and cause progressive muscle and/or motor nerve degeneration.

University of the Mediterranée and National Institute for Health and Medical Research (INSERM) researcher Nicolas Levy is the European coordinator for the NMD-Chip project. In a statement released today, Levy said that NimbleGen's high-density array technology, in conjunction with new bioinformatics tools, "should completely renew our point of view on NMDs, by providing fast, reliable and accurate answers, at a much lower cost than ever before."

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.